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Abstract
Background: Taxol binds to the cellular microtubules and suppresses their dynamic instability.
Development of tumor cell resistance to taxol is typically associated with increased expression of
the drug efflux pump P-glycoprotein and/or alterations in the microtubules. Recently, changes in
the dynamic instability of the microtubules have also been associated with development of taxol
resistance in a lung cancer cell line. We have established a 250-fold taxol-resistant human ovarian
carcinoma subline (2008/13/4) that does not display the typical alterations associated with
development of drug resistance.
Results: Utilizing the mRNA differential display technique, we observed increased expression of
an alpha subunit of the guanine nucleotide-binding protein, Gαi1, in the taxol-resistant human
ovarian carcinoma cell lines compared to the parental 2008 cells. Several isoforms of the α-subunit
of the G protein have been identified and the Gαi (inhibitory) are so named because they inhibit
the activity of adenylate cyclase leading to inactivation of the cAMP-dependent protein kinase A
(PKA) pathway. In addition, Gαi1 is also known to bind to microtubules and activates their GTPase
activity and thus induces depolymerization of the microtubules. In the present study we
demonstrate that the intracellular level of cAMP and the PKA activity were higher in the taxol-
resistant 2008/13/4 and the 2008/17/4 cells despite the increased expression of Gαi1 in these cells.
Moreover, Gαi1 was found to be localized not on the cell membrane, but in intracellular
compartments in both the taxol-sensitive and -resistant human ovarian carcinoma cells.
Interestingly, increased association of the Gαi1 protein and the microtubules in the taxol-resistant
cells compared to the parental 2008 cells was observed, both prior to and after treatment of these
cells with taxol.
Conclusion: Based on the opposing effects of taxol and the Gαi1 protein on the microtubule
dynamic instability (taxol suppresses microtubule dynamic instability whilst the Gαi1 protein
inhibits the suppression) our results indicate the operation of a novel pathway that would enable
the cells to escape the cytotoxic effects of taxol.
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Background
The antimitotic anticancer drug paclitaxel (taxol) has a
unique mechanism of action: unlike other mitotic spindle
poisons (viz. vinca alkaloids), taxol binds to the N-termi-
nal end of β-tubulin and promotes microtubule assembly
[1-3]. The effect of taxol on the microtubule dynamics has
been studied extensively in cell free systems as well in liv-
ing cells [4-6]. Observations thus made indicate taxol-
induced suppression of microtubule dynamics inhibits
the rate and extent of shortening of microtubules causing
aberrant mitotic spindles formation and cell cycle arrest
[4-6].
Overexpression of P-glycoprotein (P-gp; which functions
as a drug efflux pump, [7,8]) is the common phenotype
observed in taxol-resistant tumor cells. In addition, con-
sidering its intracellular target, it is not surprising that
resistance to taxol has also been associated with altera-
tions in microtubules resulting in reduced drug-binding
affinity or decreased intracellular levels of polymerized
tubulin and/or changes in expression of specific tubulin
isotypes [8-10]. Recently, Goncalves et al. reported associ-
ation of increased microtubule dynamics with taxol resist-
ance in lung cancer cells [11]. However, they did not
identify the cellular mediators of the increased dynamic
behavior of microtubule in the taxol-resistant cells.
We have established a series of taxol-resistant human
ovarian adenocarcinoma cell lines [12]. The > 1500-fold
taxol-resistant 2008/17/4 cell line displayed the classical
multidrug resistance phenotype with overexpression of P-
gp and cross-resistance to other natural product drugs
[12]. In contrast, the 2008/13/4 cell line, which was 252-
fold resistant to taxol relative to the parental cell line
(2008), did not exhibit overexpression of the P-gp and/or
alterations in the microtubules [12]. The intracellular
accumulation of taxol in the 2008/13/4 cells was similar
to that observed in 2008 cells. The in vitro binding of taxol
to microtubules semi-purified from the 2008/13/4 and
2008 cells was also identical [12]. The basal levels of vari-
ous α- and β-tubulin isotypes (except Bα-1) as well as
polymerized tubulin were similar in the taxol-resistant
and the parental cells (unpublished observation). This
suggests that mechanisms not hitherto identified and not
typically associated with development of taxol-resistance
were operative in the 2008/13/4 sub-line. Considering the
potential utility of taxol in the treatment of primary and
cisplatin-resistant ovarian cancers, it was of great clinical
importance to elucidate these mechanisms. Employing
the mRNA differential display analysis we identified an
increased expression of a protein involved in the G-pro-
tein coupled signal transduction pathway, named Gαi1,
in the taxol-resistant cells compared to the parental cell.
The Gα proteins, based on sequence comparisons are sub-
divided into four classes, Gs, Gi, Gq and G12-13. The Gαi
is the regulatory signaling molecule that inhibits the ade-
nylate cyclase activity [13]. Increased expression of Gαi1
could potentially inhibit the adenylate cyclase activity and
thus the cAMP mediated signal transduction (that act
through the PKA). Decrease in the PKA activity leads to
activation of the mitogen-activated protein kinase
(MAPK) pathway initiated by c-raf-1 [14]. In resting cells,
the Gαi forms a heterotrimeric complex (with the β- and
γ- subunits of guanine nucleotide binding protein) that
provides signal coupling through a series of G-protein
coupled receptors [13]. Upon activation by an appropriate
signal, the receptor interacts with the plasma membrane
bound heterotrimeric G-protein complex and catalyzes
the exchange of bound GDP for GTP in the α-subunit.
Subsequently, the GTP-bound Gα subunit and the βγ-sub-
unit dissociate from the receptor as well as from each
other. The "active" α-subunit and the "free" βγ-subunit
initiate cellular response by altering the activity of intrac-
ellular effector molecules [13].
However, recent studies have indicated that a large frac-
tion of the Gαi proteins show perinuclear localization
[15,16]. In addition, Roychowdhury et al. [17] have dem-
onstrated that Gαi1 specifically binds to the microtubules
and activates the GTPase activity of tubulin resulting in
increased microtubule dynamic instability and increased
depolymerization of the microtubules. We thus hypothe-
sized that increased Gαi1 association with the microtu-
bules in the taxol-resistant cells would be sufficient to
inhibit the taxol-induced suppression of microtubule
dynamic instability such that it would allow the taxol-
bound microtubules to depolymerize. This would nega-
tively influence the cytotoxic effects of taxol (on the for-
mation of stable microtubules leading to mitotic arrest)
and provide a mechanism via which drug-resistant cells
would be able to evade the cytotoxic effects of taxol. Based
on our results presented in this study as well as those of
Roychowdhury et al. [17] and Goncalves et al. [11], it is
conceivable that increased binding of Gαi1 with the
microtubules in the drug-resistant cells could inhibit
taxol-induced suppression of microtubule dynamics, thus
allowing cells to complete mitosis.
Results
Two distinct taxol-resistant sublines were utilized in this
study. The 2008/17/4 subline displays a classical MDR
phenotype; an increased expression of the P-gp and
decreased intracellular taxol accumulation [12]. In con-
trast, the 2008/13/4 subline has negligible P-gp expres-
sion and no defect in the intracellular accumulation of
taxol [12]. The basal levels of tubulin expression were sim-
ilar in the parental 2008 and the taxol-resistant 2008/13/
4 cells and the in vitro binding affinities of taxol to purifiedJournal of Molecular Signaling 2006, 1:3 http://www.jmolecularsignaling.com/content/1/1/3
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microtubules derived from these cells were not signifi-
cantly different [12].
Differential expression of Gαi1 in the taxol-resistant cells
To identify genes whose expression is either induced or
reduced in the taxol-resistant cells, we systematically com-
pared mRNA display patterns between parental (2008)
and the taxol-resistant (2008/13/4 and 2008/17/4) cells.
We choose only those bands that showed a consistent dif-
ferential expression in the duplicate samples from the
2008/13/4 cells and/or 2008/17/4 cells compared to the
2008 cells. Furthermore, we chose only those bands that
exhibited at least 3-fold change in densitometric intensity.
We thus identified the upregulation of the alpha-i1 subu-
nit of the guanine nucleotide binding protein mRNA
(Gαi1; data not shown) in the 2008/13/4 and 2008/17/4
cells compared to the 2008 cells. The increased expression
of the Gαi1 in the taxol resistant cells was confirmed by
Northern and Western blotting analysis. As shown in Fig-
ure 1, a 15-fold and 6-fold higher expression of Gαi1
(protein and mRNA, respectively) was observed in the
2008/13/4 and 2008/17/4 cells, respectively, compared to
the 2008 cells.
The effect of taxol on the cAMP levels and PKA activity in 
the parental and taxol-resistant cells
The Gαi is a regulatory signaling molecule that inhibits
the adenylate cyclase activity [13]. Increased expression of
Gαi1 could potentially inhibit the adenylate cyclase activ-
ity and thus the cAMP mediated signal transduction (that
act through the PKA). We assessed the basal levels of
cAMP as well as the basal PKA activity in the parental and
Expression of Gαi1 in the taxol-sensitive and -resistant cells Figure 1
Expression of Gαi1 in the taxol-sensitive and -resistant cells. Whole cell lysate was prepared from each of the cell line 
by scraping into a buffer containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/v) Triton-X-100, 
0.5% (v/v) Nonidet P40, 2.5 mM Na pyrophosphate, 1 mM NaOV, 50 mM NaF and 1× protease inhibitor cocktail and incubated 
on ice for 15 minutes. The lysate was then centrifuged at 13,000 × g for 20 min and the supernatant was transferred to a fresh 
tube and stored at -80°C until use. Proteins (25 µg/lane) were separated on a SDS-PAG and transferred to a PVDF membrane. 
Western blotting analysis was performed using rabbit polyclonal antibody against Gαi1 and enhanced chemiluminescence rea-
gents. Expression of α-tubulin was evaluated in the same lysates to ensure equal protein concentrations in each sample. For 
Northern blotting analysis, total RNA (20 µg) extracted from each cell was separated and transferred to Nylon membrane. 
Full-length Gαi1 cDNA was used as probe. The ethidium bromide stained RNA gel is shown in the bottom right-hand corner 
to ensure equal RNA loading.
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taxol-resistant cells. Effect of taxol exposure on the intrac-
ellular levels of cAMP and the PKA activity were also eval-
uated in these cells.
The basal level of cAMP in the 2008, 2008/13/4 and
2008/17/4 cells was measured using a competitive immu-
noassay kit from Biomol Research Laboratories (Ply-
mouth Meeting, PA). Surprisingly, the basal level of cAMP
was 4.5-fold and 9-fold higher in the 2008/13/4 cells
compared to the 2008 and 2008/17/4 cells, respectively
(Fig. 2). These results indicate that increased expression of
Gαi1 observed in the 2008/13/4 cells does not inhibit the
basal AC activity in these cells. In contrast, treatment (for
16 hr) with increasing concentration of taxol did not alter
the cAMP levels in the 2008, 2008/13/4 and 2008/17/4
cells significantly. It is likely that exposure to taxol causes
a mild inhibition of adenylate cyclase activity with the
resultant insignificant decrease in the intracellular levels
of camp observed (Fig. 2).
We then determined the activity of cAMP-dependent Pro-
tein kinase A in the parental and taxol-resistant cells. As
shown in Fig. 3, the PKA activity in the untreated 2008
cells was 8 units/mg protein and it was 4-fold (32 units/
mg protein) and 2.5-fold (21 units/mg protein) higher in
the 2008/13/4 and the 2008/17/4 cells, respectively.
Treatment (for 16 hr) with increasing concentrations of
taxol did not significantly affect the PKA activity in any of
the cell lines studied (Fig. 3).
Based on these observations we concluded that overex-
pression of Gαi1 in the 2008/13/4 and 2008/17/4 cells
does not inhibit the cAMP-dependent signal transduction
pathways, otherwise inhibition of adenylate cyclase (due
to increased activity of Gαi1) would have led to a decrease
in the intracellular levels of cAMP and a decrease in the
activity of the cAMP-dependent PKA.
Association of Gαi1 with the microtubules in taxol 
resistant cells
Results presented thus far indicate that the mode of action
of Gαi1 in the taxol-resistant cells maybe distinct from its
ability to inactivate AC. Recent studies have demonstrated
that Gαi1 specifically binds to the microtubules and acti-
vates the GTPase activity of tubulin [17]. Considering that
the cellular target of taxol is the microtubule, we wanted
to investigate whether alterations in the interaction of
Gαi1 with the microtubules accompanied development
of taxol resistance in the 2008/13/4 and the 2008/17/4
cells.
Intracellular cAMP levels in the parental and taxol resistant cells before and after treatment with taxol Figure 2
Intracellular cAMP levels in the parental and taxol resistant cells before and after treatment with taxol. cAMP 
levels were determined using an acetylated version of a cAMP measurement kit from Biomol Research Laboratories. A stand-
ard curve of known concentrations of acetylated cAMP was generated for each experiment. Untreated and taxol treated (16 
hr) cells were processed as described (see Materials and Methods section). The cAMP level in the taxol resistant cells was 
compared with those observed in the 2008 cells (5.6 ± 1.1 pmol/mg protein; mean of 5 experiments each performed in dupli-
cate) considered as 1.Journal of Molecular Signaling 2006, 1:3 http://www.jmolecularsignaling.com/content/1/1/3
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Utilizing confocal microscopy (Fig. 4) and differential
extraction (Figs. 5, 6), we now show an increased associa-
tion of Gαi1 with the microtubules in the taxol-resistant
cells compared to the sensitive cells, both prior to and
after treatment with taxol. It is noteworthy here that vinc-
ristine, an anticancer drug known to depolymerize micro-
tubules did not increase the association of Gαi1 with the
microtubules in either the 2008 or the 2008/13/4 and
2008/17/4 cells (Figs. 4 and 7).
As shown in Fig. 4, a distinctly cytoplasmic localization of
the Gαi1 protein (green) was observed in all the cell lines
studied. The microtubules (red) were also stained with
antibodies directed against β-tubulin. Co-localization of
Gαi1 with microtubules (assessed by presence of yellow
coloration) was not observed in the untreated 2008 cells,
but was clearly visible in the taxol-resistant 2008/13/4
and 2008/17/4 cells. Moreover, treatment with taxol
induced a time-dependent increase in the association of
Gαi1 protein and the microtubule network in the taxol-
resistant cells. This phenomenon was completely absent
in the parental 2008 cells at 4 and 24 hr post-treatment
with taxol. However, after 24 hr exposure to taxol, a few
2008 cells (<1%) displayed spotty co-localization of the
Gαi1 protein with the microtubules. We also evaluated
the effects of vincristine on the distribution of cellular
Gαi1 protein. As shown in Fig. 4, treatment with vincris-
tine decreased the association of the Gαi1 protein with
the microtubules in the taxol-resistant cells without affect-
ing its localization in 2008 cells. These results clearly illus-
trate that Gαi1 is differentially associated with the
microtubules in the taxol-resistant cells in response to
taxol.
In addition to the in-situ localization of the Gαi1 with the
microtubules we also evaluated the association of Gαi1
with the microtubules and the effect of taxol treatment on
this association in the 2008 and the 2008/13/4 cells uti-
lizing a differential extraction procedure. As shown in Fig.
5, utilizing 5 µg protein/lane, Gαi1 was not found to be
associated with the cytoskeletal fraction in the untreated
2008 cells or the 2008/13/4 cells. However, it should be
pointed out that increasing the protein concentration to
30 µg does demonstrate a low basal level of Gαi1 bound
to the cytoskeletal fraction in the 2008 and the 2008/13/
4 cells (as shown in Fig. 7). Treatment of 2008 cells with
25 nM (IC50) or 500 nM (20 × IC50) concentration of taxol
did not induce binding of Gαi1 with the microtubules. In
marked contrast, treatment of the 2008/13/4 cells with
500 nM or 5 µM (IC50) concentration of taxol demon-
strated a dose-dependent increase in the presence of Gαi1
in the cytoskeletal fraction.
Next, we evaluated the distribution of Gαi1 in the various
cellular fractions (cytoplasmic, cytoskeletal, membrane
and nuclear) before and after treatment with taxol in the
2008, 2008/13/4 and 2008/17/4 cells. As shown in Fig. 6,
expression of Gαi1 was significantly higher in the whole
cell lysates of untreated 2008/13/4 and 2008/17/4 cells
compared to 2008 cells. Treatment with taxol did not
affect the levels of Gαi1 in the 2008/13/4 whole cell
lysate, however a significant decrease in Gαi1 levels was
observed in the whole cell lysate obtained from 2008 and
2008/17/4 cells treated with taxol for 24 hr. Very low to
negligible levels of Gαi1 were observed in the membrane
fraction from each cell line (data not shown) and treat-
ment with taxol did not increase the Gαi1 levels in the
membrane fraction. Localization of Gαi1 in the nuclear
fraction was not observed in any cell lines (data not
shown). Similar to results obtained earlier (Fig. 5), associ-
ation of Gαi1 with the microtubules was not observed at
any time (before or after taxol treatment) in the 2008
cells. In contrast, a time-dependent increase in the parti-
tioning of Gαi1 to the cytoskeletal fractions was observed
in the 2008/13/4 cells. In case of the 2008/17/4 cells, a
significant fraction of Gαi1 was already associated with
the microtubules in the untreated cells, which was not
affected by taxol treatment. When we evaluated the local-
ization of Gαi1 in the cytoplasmic fraction in untreated
and taxol- treated cells, we observed that levels of soluble
PKA activity in the parental and taxol resistant cells before  and after treatment with taxol Figure 3
PKA activity in the parental and taxol resistant cells 
before and after treatment with taxol. PKA activity was 
determined using the Pierce Colorimetric Assay Kit that uti-
lizes a fluorescent-labeled Kempeptide (a PKA-specific pep-
tide (LRRASLG) substrate). Untreated and taxol treated cells 
were homogenized in a Dounce homogenizer (10 strokes 
with a tight fitting pestle) in a buffer containing 25 mM Tris-
HCl, pH 7.4, 0.5 mM EDTA, 0.5 mM EGTA, 10 mM DTT and 
protease inhibitor cocktail. The homogenate was centrifuged 
at 13,000 × g for 20 min and the PKA activity was measured 
(in triplicate) in the supernatant fraction. Values shown are 
mean ± SD of 3 separate experiments.Journal of Molecular Signaling 2006, 1:3 http://www.jmolecularsignaling.com/content/1/1/3
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Gαi1 in untreated 2008 and 2008/13/4 cells were similar,
while very low levels of soluble Gαi1 were observed in the
2008/17/4 cells. The latter could be due to increased asso-
ciation of Gαi1 and microtubules in the untreated 2008/
17/4 cells. Treatment with taxol for 24 hr decreased the
levels of soluble Gαi1 in all the cell lines. Based on these
observations and those reported in Fig. 4 (in-situ immu-
nolocalization using confocal microscopy) we hypothe-
size that while decrease in the levels of cytoplasmic Gαi1
in the 2008 cells could be a direct result of increased deg-
radation of the protein, decrease in the soluble Gαi1 in
response to taxol in the 2008/13/4 cells and possibly
2008/17/4 cells is due to an increased partitioning of the
Gαi1 from the cytoplasmic fraction to the cytoskeletal
fraction.
We next determined whether the differential partitioning
of Gαi1 to the microtubule fraction in the taxol-resistant
cells was drug-specific (Figure 7). We treated the parental
and taxol-resistant (2008/13/4) cells with vincristine and
assessed the levels of Gαi1 in the whole cell lysate and in
the cytoskeletal fraction. Vincristine was utilized because
it is (like taxol) an antimitotic anticancer drug, however
unlike taxol, vincristine induces depolymerization of the
microtubules. Vincristine (50 nM) decreased the level of
Gαi1 in the 2008 whole cell lysate (Figure 7, lane 2) with-
out affecting the total levels in the 2008/13/4 cells (Figure
7, lane 4). Further, in contrast to the observation made
with taxol, treatment of 2008 (50 nM) and 2008/13/4 (5
µM) cells with vincristine decreased the association of
Gαi1 with the cytoskeletal fraction (Figure 7, lanes 6 and
Immunolocalization of Gαi1 in the 2008, 2008/13/4 and 2008/17/4 cells, before and after treatment with taxol Figure 4
Immunolocalization of Gαi1 in the 2008, 2008/13/4 and 2008/17/4 cells, before and after treatment with taxol. 
To immunolocalize the Gαi1 protein, the 2008, 2008/13/4 and 2008/17/4 cells were grown on tissue culture-treated slides. 
After 48 hr, cells were treated with either taxol or vincristine (50 nM in case of 2008 cells, and 5 µM in case of the 2008/13/4 
and 2008/17/4 cells) for 4 hr and 24 hr. At the end of each time period, the cells were fixed with 4% (w/v) paraformaldehyde 
and processed for immunostaining. After blocking nonspecific binding sites by incubating the slides with 5% (v/v) normal goat 
serum, the slides were incubated with primary antibody directed against Gαi1 (1:100 rabbit polyclonal) and β-tubulin (1:200 
mouse monoclonal) for 1 hr. After washing in chilled PBS (3×), the slides were incubated with FITC-conjugated anti-rabbit anti-
body or rhodamine-conjugated anti-mouse antibody for 30 min. At the end of the incubation, the slides were washed again in 
PBS and mounted in media containing anti-fade. Localization of Gαi1 and β-tubulin was accomplished using an Olympus Confo-
cal microscope.Journal of Molecular Signaling 2006, 1:3 http://www.jmolecularsignaling.com/content/1/1/3
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8, respectively). These results suggest that the differential
partitioning of Gαi1 to the microtubule fraction observed
in the taxol-treated drug-resistant cells is indeed drug-spe-
cific providing further evidence that Gαi1 may be
involved in inhibiting the taxol-induced suppression of
microtubule dynamics.
Discussion
Heterotrimeric G proteins transduce signals by virtue of
their localization in close juxtaposition with the G-pro-
tein coupled receptors on the cytoplasmic side of the
plasma membrane [13]. Activated receptors induce
exchange of GDP for GTP on the Gα subunit and thus
mediate the dissociation of Gα and βγ-subunits [13]. Dis-
sociated Gαi1 decreases cAMP levels (due to inhibition of
adenylate cyclase) and thus suppresses the cAMP-depend-
ent PKA pathway. However, in the present study despite
increased expression of Gαi1, under basal conditions and
in the presence of taxol, intracellular cAMP levels as well
as the PKA activity was higher in the taxol-resistant cells
(Figs. 2 and 3) compared to the parental cells and >95%
of the Gαi1 displayed intracellular localization (either in
the cytoplasmic and/or in the cytoskeletal fraction; Fig. 4,
5, 6) in the parental and taxol-resistant cells. Furthermore,
treatment with taxol induced a differential partitioning of
Gαi1 in the cytoskeletal fraction specifically in the 2008/
13/4 and 2008/17/4 cells.
These results suggest that the biochemical machinery nec-
essary for targeting of Gαi1 is not operative under basal
conditions or under conditions of stress associated with
exposure to taxol either in the parental or in the taxol-
resistant cells. Several studies indicate that covalent mod-
ification, including myristoylation and palmitoylation of
Gα subunits are important in its targeting to the mem-
brane [18,19]. Whilst constitutively activated mutants of
Gα subunit have been identified, their importance in the
cellular localization seems to be associated with the lack
of affinity of these mutants with the βγ-subunit partner,
an interaction necessary for membrane localization [20].
Thus, it is likely that alteration in the conformation of the
Gαi1 protein due to posttranslational modifications and/
or changes in the levels of expression of partner protein(s)
(that aid in targeting it to the microtubules) is responsible
for the differential localization of Gαi1 with the microtu-
bules in the taxol-resistant cells. Cell membrane localiza-
tion of Gαi1 is necessary for its inhibitory effect on the
adenylate cyclase pathway. The absence of Gαi1 localiza-
Taxol dose-dependent increase in the association of Gαi1 protein with the microtubules exclusively in the 2008/13/4 cells Figure 5
Taxol dose-dependent increase in the association of Gαi1 protein with the microtubules exclusively in the 
2008/13/4 cells. The 2008 and 2008/13/4 cells were seeded at a density of 1 × 106/ml and incubated under normal growth 
conditions for 36 hours. Thereafter, the 2008 cells untreated (lane 1) or treated for 24 hr with 25 nM (lane 2) and 500 nM 
(lane 3) taxol and the 2008/13/4 cells untreated (lane 4) or treated for 24 hr with 500 nM (lane 5) and 5 µM (lane 6) and then 
washed with chilled PBS (3 ×). The cytoskeletal fraction was isolated essentially as described previously [22]. Briefly, the 
attached cells were incubated in a microtubule-stabilizing buffer (0.1 M PIPES, 1 mM EGTA, 1 mM MgSO4, 2 M glycerol, pH 8.0) 
for 20 min. Thereafter, the cytosolic protein were removed by incubating the cells in the microtubule stabilizing buffer contain-
ing 0.1% NP-40 and protease inhibitor cocktail for 20 min. The cytoskeletal fraction (attached to the plastic dishes) was 
scraped into RIPA buffer (PBS containing 1% NP-40, 0.5% sodium deoxycholate and 0.1% SDS) containing protease inhibitor 
cocktail. The cytoskeletal fraction (5 µg protein/lane) was then subjected to SDS-PAGE. The separated proteins were trans-
ferred to PVDF membranes and Western blotting was performed using the polyclonal antibody against Gαi1.Journal of Molecular Signaling 2006, 1:3 http://www.jmolecularsignaling.com/content/1/1/3
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tion to the cell membrane in the taxol-sensitive and -
resistant human ovarian cancer cell lines used in this
study, could explain the lack of correlation between the
increased intracellular levels of Gαi1 in the taxol-resistant
cells with the cellular cAMP content and the activity of
PKA in these cells.
Gαi1 is expressed in the 2008, albeit at levels lower than
in the taxol-resistant cells; thus it is unclear as to why spe-
cific targeting of Gαi1 to the microtubules (before and
after treatment with taxol) is observed only in the taxol-
resistant cells. Whilst it is possible that differential post-
translational modification of the Gαi1 protein could
account for its microtubule targeting in the taxol-resistant
cells it is also likely that treatment of 2008/13/4 cells with
taxol induces (a) the expression of a "chaperone" protein
(bound to the microtubules and expressed only in the
taxol-resistant cells) that could bind the soluble Gαi1 and
thereby increase its association with the cytoskeleton or
(b) binding of Gαi1 with a "chaperone" protein increases
the ability of the complex to interact with the microtu-
bules. While a third possibility exist; i.e., alteration in the
microtubules themselves such that it increases the affinity
of Gαi1 binding, such a change would lead to constitu-
tively increased association of the Gαi1 with the microtu-
bules, a phenomenon not observed in the 2008/13/4
cells.
We had originally hypothesized that the observed upreg-
ulation of the G-proteins might function via the adenylate
cyclase – cAMP – PKA-mediated signal transduction path-
way in the development of taxol resistance. In case of the
2008/13/4 cells, although changes were identified in this
pathway these could not be directly attributed as an effect
of increased expression of the Gαi1. These observations
make a compelling argument that other subtle and
Differential partitioning of Gαi1 to the microtubule fraction in the taxol-resistant cells Figure 6
Differential partitioning of Gαi1 to the microtubule fraction in the taxol-resistant cells. The 2008, 2008/13/4 and 
2008/17/4 cells were seeded at a density of 1 × 106 cells/plate and allowed to incubate in complete growth media for 36 hours. 
The cells were then treated with taxol (500 nM) for the indicated time. At the end of each time period, cells were processed 
for extraction of whole cell lysates (as described in Fig. 1), cytoskeletal fractions (as described in Fig. 5), cytoplasmic and 
nuclear fraction (utilizing the protocol supplied by manufacturer of the NE-PER extraction kit) and membrane fraction (utilizing 
the single step Mem-PER extraction kit). Protein (5 – 20 µg/lane) from each fraction were resolved on a 12% (w/v) SDS-PAG 
and then transferred to a PVDF membrane. Western blotting was performed utilizing the Gαi1 polyclonal antibody.Journal of Molecular Signaling 2006, 1:3 http://www.jmolecularsignaling.com/content/1/1/3
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uncommon effects of the Gαi1 may be involved in the
development of taxol resistance observed in the 2008/13/
4 and 2008/17/4 cells.
In addition to being membrane bound, several reports
[15,16] including the present study have demonstrated
that the Gαi1 protein is present in the perinuclear region
of the cell and is probably involved in transfer of signals
from cell surface receptors to intracellular effector mole-
cules. Wang et al. recently demonstrated that the tubulin
binds to purified Gαi1 and Gαs protein with high specifi-
city but not to other members of the Gαi family of pro-
teins [21]. Furthermore, Roychowdhury et al.
demonstrated that binding of Gαi1 to tubulin dimers
and/or microtubules resulted in activation of tubulin
GTPase activity and modulation of microtubule polymer-
ization dynamics [17]. An elegant model of regulation of
microtubule dynamics in vivo by Gαi protein proposed
by these authors suggest that binding of the G-protein to
the end of a microtubule induces hydrolysis of GTP and
subsequent loss of the stabilizing cap, resulting in micro-
tubule depolymerization (a catastrophe event) [17]. In
contrast, binding of taxol to microtubule leads to stabili-
zation of microtubule polymer, in other words suppres-
sion of dynamic instability of microtubules (4–6). Taken
together, it is very attractive to speculate that the increased
expression of the Gαi1 protein would be able to induce
depolymerization of the taxol-stabilized microtubule pol-
ymers in the taxol resistant 2008/13/4 and the 2008/17/4
cells, resulting in completion of mitosis and subsequent
cell division.
Conclusion
We hypothesize that all else being equal, the presence of
increased quantity of Gαi1 protein in the vicinity of the
taxol-bound microtubules is likely to negate the suppres-
sive effects of the drug and allow microtubules to depo-
lymerize at the end of mitosis and complete the cell cycle.
The notion is that Gαi1 with its ability to activate the
intrinsic tubulin-GTPase activity will enable taxol-stabi-
lized microtubules to depolymerize. Studies are underway
in this laboratory to ascertain whether such a phenome-
non occurs in vitro utilizing microtubules purified from
the taxol resistant cells.
Effect of Vincristine on the levels of Gαi1 in the whole cell lysate and cytoskeletal fraction from 2008 and 2008/13/4 cells Figure 7
Effect of Vincristine on the levels of Gαi1 in the whole cell lysate and cytoskeletal fraction from 2008 and 2008/
13/4 cells. The protein lysate (30 µg/lane) from untreated (lane 1,3,5,7) and vincristine treated (lane 2, 4, 6, 8) 2008 (lanes 
1,2,5,6) and 2008/13/4 (lane 3,4,7,8) cells were separated by SDS-PAGE and then transferred to PVDF membrane. Presence of 
Gαi1 was assessed as described in Fig. 1.Journal of Molecular Signaling 2006, 1:3 http://www.jmolecularsignaling.com/content/1/1/3
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Methods
Materials
Taxol was obtained from the Drug Synthesis and Chemis-
try Branch, Developmental Therapeutics Program, Divi-
sion of Cancer Treatment, National Cancer Institute,
National Institutes of Health. It was dissolved in DMSO at
a final concentration of 20 mM and the concentration of
the solvent never exceeded 0.1% in any experimental pro-
tocol. [α-32P] dCTP (3000 Ci/mmol) was purchased from
Dupont-NEN Research Products. The random priming kit
from Amersham Biosciences (Piscataway, NJ) was utilized
for radioactively labeling the Gαi1 cDNA. The enhanced
chemiluminescence reagents were from Pierce Biochemi-
cals (Rockford, IL). The antibodies utilized in this study
and their suppliers were; rabbit polyclonal Gαi1 antibody
was from Santacruz Biotechnology Inc. (Santa Cruz, CA),
mouse monoclonal β-tubulin antibody was from BD Bio-
sciences (San Diego, CA), rhodamine-conjugated anti-
mouse antibody and the FITC-conjugated anti-rabbit anti-
body was from Pierce Biochemicals (Rockford, IL).
Cell lines
The parental human ovarian carcinoma cells, 2008 and its
taxol-resistant derivatives (2008/13/4 and 2008/17/4)
were maintained as described previously [12]. The 2008/
13/4 and the 2008/17/4 cells were derived by exposure of
the 2008 cells to stepwise increasing concentrations of
taxol [12]. The 2008/13/4 cells are cross-resistant to other
antimitotic drugs (viz., vincristine, vinblastine) and
etoposide but are not cross-resistant to adriamycin and
cisplatin. The 2008/13/4 cells have no defect in the trans-
port of taxol, express negligible levels of P-glycoprotein
and are 252-fold resistant to taxol compared to the 2008
cells. In contrast the > 1500-fold taxol-resistant 2008/17/
4 cells display a classic multidrug resistant phenotype
with cross-resistance to all natural product drugs tested,
expression of high levels of P-glycoprotein and a signifi-
cant defect in the intracellular accumulation of taxol.
However, the binding of taxol to microtubules is similar
in the taxol-resistant and the parental cells [12].
Intracellular cAMP levels
The intracellular cAMP levels in the 2008, 2008/13/4 and
2008/17/4 cells were determined using an acetylated ver-
sion of a cAMP measurement kit from Biomol Research
Laboratories (Plymouth Meeting, PA). A standard curve of
known concentrations of acetylated cAMP was generated
for each experiment. The cAMP level (pmol/mg protein)
in the taxol resistant cells was compared with those
observed in the 2008 cells considered as 1.
cAMP-dependent PKA activity
PKA activity was determined using the Pierce Colorimetric
Assay Kit (Rockford, IL) that utilizes a fluorescent-labeled
Kempeptide (a PKA-specific peptide (LRRASLG) sub-
strate). The parental and taxol-resistant cells were seeded
at a density of 2 × 106 cells/100 mm plate and incubated
for 24 hr. Thereafter, the cells were either left untreated or
treated with varying concentrations of taxol for the indi-
cated time periods. Untreated and taxol treated cells were
homogenized in a Dounce homogenizer (10 strokes with
a tight fitting pestle) in a buffer containing 25 mM Tris-
HCl, pH 7.4, 0.5 mM EDTA, 0.5 mM EGTA, 10 mM DTT
and protease inhibitor cocktail. The homogenate was cen-
trifuged at 13000 × g for 20 min and the PKA activity was
measured (in triplicate) in the supernatant fraction as per
the instructions of the kit supplier. Values shown are
mean ± SD of 3 separate experiments.
Protein preparations
The 2008, 2008/13/4 and 2008/17/4 cells were seeded at
a density of 1 × 106/ml and incubated under normal
growth conditions for 36 hours. Thereafter, the cells were
left untreated or treated with varying concentrations of
taxol or vincristine for the indicated time periods. At the
end of each time period the cells were washed with chilled
PBS (3 ×) and various protein fractions were extracted as
outlined below.
Whole cell lysate
Whole cells lysate was prepared from each of the cell line
by scraping cells into a buffer containing 20 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (v/
v) Triton-X-100, 0.5% (v/v) Nonidet P40, 2.5 mM sodium
pyrophosphate, 1 mM sodium orthovanadate, 50 mM
sodium fluoride and 1× protease inhibitor cocktail and
incubating on ice for 15 minutes. Then, the lysate was cen-
trifuged at 13,000 × g for 20 min and the supernatant was
transferred to a fresh tube and stored at -80°C until use.
Proteins were separated on a SDS-PAG and transferred to
a PVDF membrane. Western blotting analysis was per-
formed using rabbit polyclonal antibody against Gαi1
(Santacruz Biotechnology Inc., Santa Cruz, CA) and
enhanced chemiluminescence reagents from Pierce Bio-
chemicals (Rockford, IL).
Cytoskeletal protein fraction
The cytoskeletal fraction was isolated essentially as
described previously [22]. Briefly, the attached cells will
be incubated in a microtubule-stabilizing buffer (0.1 M
PIPES, 1 mM EGTA, 1 mM MgSO4, 2 M glycerol, pH 8.0)
for 20 min. Thereafter, the cytosolic protein were removed
by incubating the cells in the microtubule stabilizing
buffer containing 0.1% NP-40 and protease inhibitor
cocktail for 20 min. The cytoskeletal fraction (attached to
the plastic dishes) was scraped into RIPA buffer (PBS con-
taining 1% NP-40, 0.5% sodium deoxycholate and 0.1%
SDS) containing protease inhibitor cocktail. This selective
extraction procedure has been shown to be ideal for pre-
serving the association between the cytoskeleton andJournal of Molecular Signaling 2006, 1:3 http://www.jmolecularsignaling.com/content/1/1/3
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other associated regulatory molecules [22]. The cytoskele-
tal fraction (5 µg protein/lane) was then subjected to SDS-
PAGE. The separated proteins were transferred to PVDF
membranes and Western blotting was performed using
the polyclonal antibody against Gαi1 as described earlier.
Subcellular protein fractions
The cells were processed for the extraction of cytoplasmic
and nuclear fraction utilizing the protocol supplied by
manufacturer of the NE-PER extraction kit (Pierce Bio-
chemicals, Rockford, IL). The membrane fraction was
extracted utilizing the single step Mem-PER extraction kit
and protocol supplied by the manufacturer (Pierce Bio-
chemicals, Rockford, IL). Protein (5 – 20 µg/lane) from
each fraction were resolved on a 12% (w/v) SDS-PAG and
then transferred to a PVDF membrane. Western blotting
was performed utilizing the Gαi1 polyclonal antibody
(Santacruz Biotech, Inc., Santacruz, CA) as described
above.
Northern blotting analysis
Total RNA (20 µg) extracted from each cell line was frac-
tionated on 1% agarose-formaldehyde gel and then
stained with ethidium bromide to ensure equal RNA load-
ing. Thereafter the RNA was transferred to a Nylon mem-
brane and probed with a full-length Gαi1 cDNA labeled
with  32P-dCTP with a random priming kit from Amer-
sham Biosciences (Piscataway, NJ). Hybridization was
performed at 55°C overnight and nonspecific binding
was removed by washing the nylon membrane in a high
stringency buffer at 55°C for 30 min.
Immunolocalization of Gαi1
To immunolocalize the Gαi1 protein, the 2008, 2008/13/
4 and 2008/17/4 cells were grown on tissue culture-
treated slides. After 48 hr, cells were treated with either
taxol or vincristine (50 nM in case of 2008 cells, and 5 µM
in case of the 2008/13/4 and 2008/17/4 cells) for 4 hr and
24 hr. At the end of each time period, the cells were rap-
idly rinsed in chilled PBS and then fixed with 4% (w/v)
paraformaldehyde and processed for immunostaining.
After blocking nonspecific binding sites by incubating the
slides with 5% (v/v) normal goat serum, the slides were
incubated with primary antibody directed against Gαi1
(1:100 rabbit polyclonal) and β-tubulin (1:200 mouse
monoclonal) for 1 hr. After washing in chilled PBS (3×),
the slides were incubated with FITC-conjugated anti-rab-
bit antibody or rhodamine-conjugated anti-mouse anti-
body for 30 min (Pierce Biochemicals, Rockford, IL). At
the end of the incubation, the slides were washed again in
PBS and mounted in media containing anti-fade. Locali-
zation of Gαi1 and β-tubulin was accomplished using an
Olympus Confocal microscope.
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